Oppenheimer Reiterates Outperform on Sarepta Therapeutics, Maintains $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh has reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a $180 price target.
May 26, 2023 | 3:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a $180 price target.
The reiteration of the Outperform rating and maintenance of the $180 price target by Oppenheimer analyst Hartaj Singh indicates a positive outlook for Sarepta Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100